GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes
Neves JS, Borges-Canha M, Vasques-Nóvoa F, et al.
J Am Coll Cardiol. 2023;82 (6) 517–525.
Leggi
Breaking news
Safety of sodium‐glucose co‐transporter‐2 inhibitors on amputation across categories of baseline cardiovascular disease and diuretics use in patients with type 2 diabetes
Park S, Jeong HE, Bea S, et al.
Diabetes Obes Metab. Pub. online 28 Jul 2023.
Leggi
Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records
Xie Y, Bowe B, Xian H, et al.
Lancet Diabetes Endocrinol. 2023;S2213-8587(23)00171-7.
Leggi
Baseline Cardiovascular Risk Factor Control in Patients With Type 2 Diabetes and Coronary Disease Versus Stroke: Secondary Analysis of Cardiovascular Outcome Trials
Balasubramanian P, Kernan WN, Sheth KN, et al.
Stroke. 2023;54(8):2013-2021.
Leggi
Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists
Alhiary R, Kesselheim AS, Gabriele S, et al.
JAMA. Pub. online 28 Jul 2023.
Leggi
Effects of sodium-glucose co-transporter 2 inhibitors by background cardiovascular medications: A systematic review and meta-analysis
Avgerinos I, Karagiannis T, Matthews DR, et al.
Diabetes Obes Metab. Pub. online 12 Jul 2023.
Leggi
Evaluation of insulin pump infusion sites in type 1 diabetes: the DERMIS study
Kalus A; Shinohara MM, Wang R, et al.
Diabetes Care. 2023 Jul 14;dc230426.
Leggi
Oral anticoagulation across diabetic subtypes in patients with newly diagnosed atrial fibrillation: A report from the GARFIELD-AF registry
Bassand JP, Virdone S, Camm AJ, et al.
Diabetes Obes Metab. Pub. online 12 Jul 2023.
Leggi
Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus
Sacks DB, Arnold M, Bakris GL, et al.
Diabetes Care. 2023;dci230036
Leggi